CClinicalTrials.gg
Not yet recruitingNCT07797998Updated Sep 1, 2026

Association of Diet and IBD

An observational study in IBD and Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), sponsored by Assiut University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Assiut University · Observational

Study type
Observational
Model
Case-crossover
Time perspective
Cross-sectional
Enrollment
100
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The study investigate the nutritional status and inflammatory markers and diet inflammatory index in patients with IBD and their effect on disease activity.

Read the detailed description

The prevalence of inflammatory bowel diseases [IBD] has risen over the past decade to become a global concern. Malnutrition is one of the major issues in patients who suffer from IBD, including both CD and UC. In published studies, approximately three-quarters of patients with active IBD have protein-energy malnutrition . It is a serious concern because it links with a higher risk of infections, weak outcomes, poor prognosis, and bad post-surgical recovery . Nutrition status in IBD plays a vital role since it can alter disease activity and affect morbidity. Not only does malnutrition affect disease activity, but the dietary inflammatory potential of the diet also affects the progression and therapeutic success in IBD patients. The dietary inflammatory potential refers to the ability of a dietary pattern or specific foods to either promote or reduce inflammation in the body. Dietary components may have anti- or pro-inflammatory potentials, which can be evaluated with indices such as the Dietary Inflammatory Index (DII). DII stands out for its particular emphasis on the connection between food consumption and the development and aggravation of inflammation. Therefore, it seems sense to assess this relationship in IBD patients. There are, however, few research on the pro-inflammatory potential of diet as determined by dietary indicators and their influence on IBD activity, and the findings are equivocal.

Inflammation and abnormalities in the immune system appear to be a critical factor in the development of IBD. Therefore, noninvasive inflammatory biomarkers may help as a noninvasive, easier accessible way to detect IBD activity state than Colonoscopy, which is the most sensitive and specific diagnostic step for diagnosing and determining the disease activity and severity.

Complete blood count (CBC)-derived inflammatory indices are inexpensive, widely available mathematical formulas. They act as reliable, non-invasive proxy markers for systemic inflammation, disease activity, and immune function by tracking the balance between innate and adaptive immune cells Therefore, in our study, we aim to assess the effect of nutritional status on IBD activity and the role of inflammatory biomarkers as a simple method to determine disease activity.

02

Conditions studied

  • IBD
  • Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)

Keywords

  • Diet inflammation index
  • ibd
  • nutritional status
  • Hematological Inflammatory Biomarkers
  • disease activity
03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study include People with IBD from Egypt

Inclusion criteria

  • Patients aged 18-65 years.
  • patients diagnosed with either Crohn's disease or ulcerative colititis

Exclusion criteria

Exclusion Criteria:

  • Patients with previously identified thyroid illness.
  • Patients with acute infection.
  • Patients with major surgeries or recent trauma within the last 6 months.
  • Patients known to have a malignancy.
  • Patient with a previous history of bariatric surgery.
04

Study design

Observational model
Case-crossover
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No
05

What researchers measure

Primary outcomes

  1. Nutritional Status Assessed by the Subjective Global Assessment (SGA) Score.

    Nutritional status is assessed using the Subjective Global Assessment (SGA) tool. The scale categorizes patients from A (well-nourished) to C (severely malnourished). A higher alphabetical category (C) indicates a worse nutritional outcome.

    Time frame: baseline and up to one year

  2. Disease Activity Assessed by the Crohn's Disease Activity Index (CDAI)..

    Disease activity in Crohn's disease patients is evaluated using the Crohn's Disease Activity Index (CDAI). The theoretical score ranges from 0 to 600. Higher scores indicate a worse outcome (greater disease severity).

    Time frame: Baseline, Week 8, and Week 24

  3. Disease Activity in Ulcerative Colitis.

    Disease activity in ulcerative colitis patients is evaluated using the Mayo Score. The score ranges from 0 to 12. Higher scores indicate a worse outcome (greater disease severity).

    Time frame: Baseline, Week 8, and Week 24

Secondary outcomes

  1. Pearson Correlation Coefficient Between Dietary Inflammatory Index (DII) Scores and disease activity in IBD Patients.

    The correlation between the inflammatory potential of the diet and Crohn's disease activity will be evaluated. Diet is assessed via the Dietary Inflammatory Index (DII) derived from a Food Frequency Questionnaire. The DII is a continuous scale where higher scores indicate a more pro-inflammatory diet. Disease activity is assessed via the CDAI (scale: 0-600, higher scores indicate a worse outcome).

    Time frame: Baseline, Week 8, and Week 24

06

Study locations

1 site
  • Assiut University
    Asyut, Egypt
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07797998
Lead sponsor
Assiut University
Responsible party
Gamal Abd-Elnaser Abd-Elbar Osman (assistan lecturer, Assiut University) — Principal investigator
First posted
Sep 1, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Jan 1, 2028 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Sep 1, 2026

Study contacts

Gamal A Abd-Elbar, General Practitioner
Contact
gamal.18313454@med.aun.edu.eg
201028953251

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion